How Long Does a Mitral Valve Clip Last?

The mitral valve clip itself is a permanent implant made of cobalt-chromium alloy, and the device does not wear out or degrade over time. The real question is how long the repair it creates continues to work. Five-year data from the landmark COAPT trial show that the clip kept working safely in the vast majority of patients with secondary (functional) mitral regurgitation, with device-related safety events occurring in only about 1.4% of treated patients, all within the first 30 days. But “lasting” means more than just staying physically intact. Leak recurrence, the return of significant regurgitation around or through the repaired valve, is the practical measure of durability, and that story is more nuanced than the hardware alone suggests.

What the Five-Year Trial Data Actually Show

The strongest evidence on clip durability comes from the COAPT trial, which followed patients with heart failure and secondary mitral regurgitation for five years. Patients who received the clip on top of standard medical therapy had a death rate of about 57%, compared with roughly 67% in those treated with medication alone. Hospitalizations for heart failure were cut nearly in half: the annualized rate was about 33% per year in the clip group versus 57% in the medication-only group. Improvements in symptoms and heart-failure class held up at five years, and none of the clip-treated patients needed surgery for severe narrowing of the valve caused by the clip.

Those numbers deserve context. A mortality rate above 50% sounds alarming, but the patients in this trial were very sick to begin with. They had advanced heart failure and significant valve leakage despite being on maximum medical therapy. The comparison that matters is not against healthy people but against similarly ill patients who did not get the clip. After adjusting for how sick patients were at the start, the clip group had a roughly 28% lower risk of dying over five years.

A separate comparison study of high-surgical-risk patients found similar patterns: after adjusting for baseline differences, clip-treated patients had survival comparable to surgical patients and significantly better survival than those managed conservatively.

How Often Does the Leak Come Back?

This is really the durability question most patients and cardiologists care about. A recent expert overview pooling data across studies found that significant leak recurrence runs between 5% and 10% in the first months after the procedure and stays relatively stable through the first three years. By the five-year mark, recurrence climbs to around 17%, and roughly 9% of patients need some form of reintervention. The picture looks quite different depending on why the valve was leaking in the first place. Patients with primary (degenerative) mitral regurgitation, where the valve structure itself is abnormal, fare worse: about 41% experienced leak recurrence or reintervention by five years. Patients with secondary (functional) regurgitation, where the valve is structurally normal but the heart around it has enlarged, tend to see more stable results in the early years.

⁴

Early real-world registries found a consistent pattern: most recurrent leakage shows up in the first year. After that, the rate of new recurrence drops off. One study with near-complete two-year follow-up noted that very few patients developed new significant leakage between years one and four, consistent with what the EVEREST II randomized trial had also observed.

⁵

What Determines Whether the Repair Holds

The single most consistent predictor of long-term success is how much residual leak remains immediately after the clip is placed. If the valve is still leaking moderately right after the procedure, the outlook is significantly worse. A large German multicenter registry found an almost linear relationship between the severity of residual leak at the time of the procedure and the risk of dying within a year. Patients left with minimal residual regurgitation had a one-year mortality around 15%, while those with more significant residual leak were closer to 22%.

⁶

Longer-term data confirm this. Patients who left the hospital with mild or less residual leak and maintained that grade at one year had the best survival, while those who started with mild leak but worsened by 12 months did substantially worse.

⁷

The cause of the original leak matters too. In patients with primary (degenerative) regurgitation, having a “flail” leaflet segment was the strongest predictor of later recurrence, roughly quadrupling the risk. In secondary (functional) regurgitation, an enlarged left atrium was the key driver; for every 10 mL of additional atrial volume, risk ticked up progressively.

⁸

Another technical factor that affects outcomes is the pressure gradient across the valve after clipping. If the clip narrows the valve opening too much, blood has to push harder to get through, which creates its own set of problems. One study found that a pressure gradient above 5 mmHg at the time of the procedure was associated with more than double the risk of poor outcomes, and recommended that operators consider repositioning the clip if gradients are too high.

⁹

How the Clip Can Fail Mechanically

When the repair does break down, the cause depends on the type of regurgitation being treated. In primary regurgitation, the most common culprits are leaflet tears and loss of leaflet insertion, meaning the tissue that was grasped by the clip gets damaged or pulls free. In secondary regurgitation, more than half of recurrences happen without any visible damage to the clip or leaflets at all. The heart itself continues to dilate and stretch, pulling the valve leaflets apart despite the clip still being securely in place.

⁸

The most dramatic failure mode is called single leaflet detachment, where the clip loses its grip on one of the two leaflets entirely. This tends to happen early and typically causes a sudden, severe return of regurgitation. Management is tricky and frequently requires surgical repair.

¹⁰

In rare instances, the failure is truly mechanical: one case report documented the clip’s gripper component physically detaching from the main frame, a first-of-its-kind event that required open-heart surgery to fix.

¹¹

What Happens Biologically After the Clip Is Placed

One reason the clip tends to become more secure over time is that the body gradually grows tissue around it. A study examining explanted devices at different time intervals found a predictable healing sequence. In the first month, blood proteins and platelets coat the device. Over the next few months, early scar-like tissue begins to form. By about three to ten months, tissue starts bridging the space between the clip’s arms. Beyond ten months, the clip becomes fully encased in a dense, collagen-rich tissue layer, with a tissue bridge forming across the top of the device that creates continuity between the two valve leaflets on the atrial side.

¹²

This biological encapsulation is probably why acute mechanical failures like single leaflet detachment happen early or not at all. Once the tissue bridge forms, the clip is no longer relying purely on its metal grip to hold the leaflets together. The trade-off is that this same tissue growth makes subsequent surgery harder, because removing the clip means peeling it out of a living tissue cocoon.

Options When the Repair Stops Working

In the COAPT trial, only about 4% of clip-treated patients needed a repeat valve intervention over four years of follow-up. Most of those repeat procedures were another clip rather than surgery, and about 80% were successful. Patients who underwent a repeat intervention had higher rates of heart-failure hospitalization beforehand, but once the redo procedure was done, those hospitalization rates dropped sharply.

¹³

Repeat clipping works best when the original clip is still securely attached to both leaflets and the leaflet tissue is intact. If the leaflet has torn or pulled free from the clip, a second clip is much less likely to succeed.

¹⁴

When repeat clipping is not an option, surgery is the fallback. A systematic review of 172 patients who underwent mitral valve surgery after a failed clip found that valve replacement was more common than repair, because the clip and its surrounding tissue often leave the valve too damaged to salvage. In-hospital mortality was about 15%, and about a quarter of patients had died by one year. Those are sobering numbers, but they reflect the fact that these patients were extremely high-risk to begin with: 80% were in advanced heart-failure classes at the time of surgery.

¹⁵

Newer-Generation Devices and Whether They Last Longer

The original MitraClip has been through several design iterations. The current version, the G4, offers multiple clip sizes and improved steering controls compared with earlier models. A direct comparison found that the G4 achieved mild or less residual leak in about 60% of patients, compared with roughly 26% with earlier generations. That translates to a meaningfully larger reduction in leak severity, typically a three-grade drop instead of a smaller improvement.

¹⁶

There is also a competing device called the PASCAL system, which uses a slightly different approach with wider paddles and a central spacer. Head-to-head comparisons show the two devices perform similarly on short-term outcomes: procedural success around 97-98% for both, one-year survival around 87% for both, and no significant difference in residual leak or rehospitalization rates at one year.

¹⁷

Whether the improved immediate results of the G4 translate into better five- and ten-year durability is still an open question. The logic is straightforward: since residual leak after the procedure is the strongest predictor of long-term outcomes, a device that achieves less residual leak should, in theory, hold up better. But long-term head-to-head data comparing device generations do not yet exist.

The Role of Where and by Whom It Is Done

Like most complex procedures, outcomes improve with experience. Studies from large registries show that both the safety and effectiveness of clip placement get better as operators and institutions do more cases. The learning curve appears to be long, with improvements continuing even as individual operators approach 150 procedures. This is not a procedure where an operator quickly masters the technique and plateaus.

¹⁸

For a patient, the practical implication is that center volume matters. A high-volume center with experienced operators is more likely to achieve the minimal residual leak that predicts the best long-term results. If you are being evaluated for a clip procedure, asking about the center’s and operator’s case volumes is entirely reasonable.

Symptom Improvement and Quality of Life

Beyond the leak measurements and survival curves, what patients usually want to know is whether they will feel better and for how long. At baseline, roughly 80% of patients undergoing clipping are in advanced heart-failure symptom classes, meaning they are limited by breathlessness during minimal activity or even at rest. One year after the procedure, about 83% of surviving patients had improved to mild or no symptoms, and these gains held up at the five-year mark in the COAPT data.

¹⁹

Age itself does not appear to prevent benefit. An analysis from the COAPT trial found that both younger and older patients saw improvements in survival and quality of life, though older patients may get somewhat less reduction in heart-failure hospitalizations. The message from heart teams is that age alone should not disqualify someone from consideration; it is the totality of a patient’s health that matters.

²⁰

Rare but Serious Late Complications

Infection of the clip, known as endocarditis, is extremely rare, with one estimate putting the five-year rate at about 0.2%. But when it does occur, it is devastating, carrying a mortality rate as high as 50%. Case reports describe rapid leaflet destruction and emergency surgery. One report traced the infection to an organism already carried by the patient before the procedure, highlighting the importance of screening for infection before the clip is placed.

²¹

Masses found on the clip during routine follow-up imaging can create diagnostic headaches. In patients with cancer or blood disorders, it can be difficult to distinguish between infection and non-infectious clot formation on the device surface. One recent case involved an elderly patient with a blood cancer who developed a mass on her clip; the medical team struggled to determine whether it was endocarditis or a sterile clot related to her malignancy.

²²

What the Economics Suggest About Durability

Cost-effectiveness analyses, while not a direct measure of how long the clip lasts, give a useful window into its sustained value. A model based on COAPT trial data estimated that the clip adds roughly one extra year of life and about 0.8 quality-adjusted life-years over a patient’s lifetime, at a cost that falls within standard thresholds for cost-effective treatments in the United States, the United Kingdom, and Germany.

²³

Much of the savings comes from avoided hospital stays. One analysis projected about 829 fewer heart-failure hospitalizations per 1,000 treated patients over a lifetime, which represents an enormous reduction in both suffering and healthcare costs.

²⁴

These economic projections assume the repair lasts, which is itself an endorsement. If the clip routinely failed at two or three years, the hospitalization savings would evaporate and the cost-effectiveness ratios would collapse. The fact that the models hold up over a lifetime horizon reflects the accumulated clinical evidence that, for the right patients, the repair created by the clip is durable enough to sustain meaningful benefit for years.